KR960700711A - 뇌혈관성 질환의 치료 또는 예방용 약제(Medicament for treating or preventing cerebrovascular diseases) - Google Patents

뇌혈관성 질환의 치료 또는 예방용 약제(Medicament for treating or preventing cerebrovascular diseases) Download PDF

Info

Publication number
KR960700711A
KR960700711A KR1019950703760A KR19950703760A KR960700711A KR 960700711 A KR960700711 A KR 960700711A KR 1019950703760 A KR1019950703760 A KR 1019950703760A KR 19950703760 A KR19950703760 A KR 19950703760A KR 960700711 A KR960700711 A KR 960700711A
Authority
KR
South Korea
Prior art keywords
alkyl
hydrogen
compound
iii
imidazolyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019950703760A
Other languages
English (en)
Korean (ko)
Inventor
기요타카 가쓰타
히로유키 다카마쓰
요시코 우에다
하지메 나카니시
게이조 요시다
Original Assignee
후지야마 아키라
후지사와야쿠힌 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939304701A external-priority patent/GB9304701D0/en
Priority claimed from GB939320882A external-priority patent/GB9320882D0/en
Application filed by 후지야마 아키라, 후지사와야쿠힌 고교 가부시키가이샤 filed Critical 후지야마 아키라
Publication of KR960700711A publication Critical patent/KR960700711A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1019950703760A 1993-03-08 1994-02-16 뇌혈관성 질환의 치료 또는 예방용 약제(Medicament for treating or preventing cerebrovascular diseases) Ceased KR960700711A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB939304701A GB9304701D0 (en) 1993-03-08 1993-03-08 New use
GB9304701.7 1993-03-08
GB9320882.5 1993-10-11
GB939320882A GB9320882D0 (en) 1993-10-11 1993-10-11 New use
PCT/JP1994/000249 WO1994020102A2 (en) 1993-03-08 1994-02-16 Medicament for treating or preventing cerebrovascular diseases

Publications (1)

Publication Number Publication Date
KR960700711A true KR960700711A (ko) 1996-02-24

Family

ID=26302552

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950703760A Ceased KR960700711A (ko) 1993-03-08 1994-02-16 뇌혈관성 질환의 치료 또는 예방용 약제(Medicament for treating or preventing cerebrovascular diseases)

Country Status (10)

Country Link
US (3) US5607938A (enExample)
EP (1) EP0688216A1 (enExample)
JP (1) JPH08507514A (enExample)
KR (1) KR960700711A (enExample)
CN (1) CN1118990A (enExample)
AU (1) AU683447B2 (enExample)
CA (1) CA2157671A1 (enExample)
HU (1) HUT68293A (enExample)
TW (1) TW305760B (enExample)
WO (1) WO1994020102A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005367A2 (en) * 1994-08-16 1996-02-22 Beloit Technologies, Inc. Hydrostatic self-loading controlled deflection roll
ATE212860T1 (de) * 1994-09-19 2002-02-15 Fujisawa Pharmaceutical Co Eine neuartige medizinische verwendung eines 5ht 3-antagonisten
GB9819035D0 (en) * 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII
US20020127263A1 (en) * 2001-02-27 2002-09-12 Wenda Carlyle Peroxisome proliferator-acitvated receptor gamma ligand eluting medical device
US7592344B2 (en) * 2005-11-30 2009-09-22 Solvay Pharmaceuticals Gmbh NK1 and NK2-antagonists and compositions and methods of using the same
RU2340342C2 (ru) * 2006-12-07 2008-12-10 Сергей Олегович Бачурин СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ОСТРЫХ И ХРОНИЧЕСКИХ НАРУШЕНИЙ МОЗГОВОГО КРОВООБРАЩЕНИЯ, В ТОМ ЧИСЛЕ ИНСУЛЬТА, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО[4,3-b]ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
CN103755708B (zh) * 2013-12-31 2016-09-07 浙江大学 一种吲哚或吡咯并嘧啶衍生物的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH22672A (en) * 1984-01-25 1988-11-14 Glaxo Group Ltd Imidazolylmethyltetrahydrocarbazolone derivatives, composition and method of use thereof
AU583343B2 (en) * 1985-01-23 1989-04-27 Glaxo Group Limited Heterocyclic compounds
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
US4985437A (en) * 1986-12-17 1991-01-15 Glaxo Group Limited Medicaments
US5244909A (en) * 1986-12-17 1993-09-14 Glaxo Group Limited Methods for the treatment of cognitive disorders
IE60991B1 (en) * 1986-12-17 1994-09-07 Glaxo Group Ltd Use of ketone derivatives in the treatment of cognitive disorders
US5200414A (en) * 1986-12-17 1993-04-06 Glaxo Group Limited Methods for the treatment of cognitive disorders
US5190954A (en) * 1986-12-17 1993-03-02 Glaxo Group Limited Methods for the treatment of cognitive disorders
GB8805269D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
GB8820651D0 (en) * 1988-09-01 1988-10-05 Glaxo Group Ltd Medicaments
AU627221B2 (en) * 1988-09-27 1992-08-20 Fujisawa Pharmaceutical Co., Ltd. Pyridoindole derivatives and processes for preparation thereof
US5173493A (en) * 1988-09-27 1992-12-22 Fujisawa Pharmaceutical Company, Ltd. Pyridoindole derivatives and processes for preparation thereof
ATE137501T1 (de) * 1989-07-03 1996-05-15 Yoshitomi Pharmaceutical Benzazin-verbindungen und deren pharmazeutische verwendungen
US5180728A (en) * 1989-09-25 1993-01-19 Fujisawa Pharmaceutical Company, Ltd. Pyrimidoindole derivatives and processes for preparation thereof
GB8928208D0 (en) * 1989-12-13 1990-02-14 Glaxo Group Ltd Medicaments
US5098889A (en) * 1990-09-17 1992-03-24 E. R. Squibb & Sons, Inc. Method for preventing or inhibiting loss of cognitive function employing a combination of an ace inhibitor and a drug that acts at serotonin receptors
EP0492020A1 (en) * 1990-12-21 1992-07-01 Merrell Dow Pharmaceuticals Inc. Use of certain esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one and related compounds for treating cognitive disorders

Also Published As

Publication number Publication date
AU6045594A (en) 1994-09-26
CA2157671A1 (en) 1994-09-15
US5698561A (en) 1997-12-16
JPH08507514A (ja) 1996-08-13
EP0688216A1 (en) 1995-12-27
HU9402578D0 (en) 1994-11-28
US5607938A (en) 1997-03-04
WO1994020102A2 (en) 1994-09-15
CN1118990A (zh) 1996-03-20
US5866598A (en) 1999-02-02
HUT68293A (en) 1995-06-28
WO1994020102A3 (en) 1994-10-27
AU683447B2 (en) 1997-11-13
TW305760B (enExample) 1997-05-21

Similar Documents

Publication Publication Date Title
KR880011199A (ko) 신규 펩타이드 화합물, 그의 제조방법 및 그를 함유하는 약학적 조성물
KR900701282A (ko) 심장 또는 뇌의 허혈성 질환의 치료, 예방제
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
RU94041223A (ru) Средство для лечения мотонейроновых заболеваний
RU94045155A (ru) Способы ингибирования болезни альцгеймера
KR950031069A (ko) 골손실의 억제 및 혈청 콜레스테롤의 강하 방법
KR920700200A (ko) 19-노르-비타민 d 화합물
FI935847A0 (fi) L-DOPA-esterkompositioner
RU95105973A (ru) Способ снижения тяжести токсоплазмоза, фармацевтическая композиция, применение производных рифамицина для получения лекарственных препаратов для лечения токсоплазмоза
DE69125216D1 (de) Aminoalkanesulfonsäurederivate und pharmazeutische Zusammensetzungen davon zur Prävention oder Behandlung von Herzerkrankungen
KR940005274A (ko) 쇼그렌(Sjoegren)증후군 치료제
KR950007848A (ko) (S)-(-)-α-에틸-2-옥소-1-피롤리딘아세트아미드를 사용한 불안치료방법
KR950016727A (ko) 트롬보모듈린 발현을 증가시키는 방법
KR950000663A (ko) 트리테르펜 유도체 및 이를 함유하는 엔도텔린-수용체 길항물질
KR950016760A (ko) 치질 치료제
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.
KR940702726A (ko) 치환된 퀴놀린-3-카르복시아미드 화합물의 용도 및 이를 이용한 다발성 경화증의 치료방법
KR920004387A (ko) 진통제 및 피부질환 치료용 국소용 소염제로서의 4-치환된 디하이드로피리도[4,3-d]피리미딘
KR890012942A (ko) 5-치환된 오르니틴 유도체
KR927002224A (ko) 항종양효과증강제 및 항종양제
KR950016720A (ko) 아밀로이드 단백질의 효과를 저해하는 방법
KR880004810A (ko) 소화성 궤양 치료제
KR950703955A (ko) 테르피리딘 유도체의 약학적 용도
KR930702985A (ko) 식도암의 치료
KR950008502A (ko) 3-또는4-클리코실옥시벤조피란 유도체 및 활성 성분으로서 이를 함유하는 알러지치료제

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19950906

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19990211

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20001031

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20010529

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20001031

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I